GlassScriptPhysician profile
Diana C Doeing
NPI 1730341983
$13,207.69
in general payments reported to CMS, 2019-2025
12 companies · $8,602 in 2025
The $8,602 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $15.48 · 2021: $3,897 · 2022: $131 · 2023: $239 · 2024: $206 · 2025: $8,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,350 · Travel and Lodging: $943 · Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,350.00 |
| Travel and Lodging | $942.64 |
| Food and Beverage | $754.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,602.17 | 2025 | Ofev |
| Intuitive Surgical, INC. | $4,112.64 | 2021-2023 | Da Vinci Surgical System |
| Ceribell, INC. | $151.51 | 2024 | Pocket Eeg Device |
| Glaxosmithkline, LLC. | $77.63 | 2019-2021 | |
| Vapotherm INC | $59.04 | 2021-2022 | |
| Philips North America LLC | $52.35 | 2019-2023 | |
| Ethicon INC. | $38.91 | 2021 | |
| Inogen, INC. | $27.26 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $27.04 | 2019-2020 | |
| Amgen INC. | $26.85 | 2024 | Tavneos |
| Shire North American Group INC | $18.70 | 2019 | |
| Mylan Specialty L.P. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Doeing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.